| Literature DB >> 32885189 |
Noah M Ivers1,2,3,4, Monica Taljaard5,6, Vasily Giannakeas1,2, Catherine Reis1, Cara L Mulhall7, Jonathan M C Lam7, Ann N Burchell2,3,4, Gerald Lebovic3,8, Susan E Bronskill1,2,3,9.
Abstract
BACKGROUND: Antipsychotic medication use in nursing homes is associated with potential for harms. In Ontario, Canada, an agency of the provincial government offers nursing home physicians quarterly audit and feedback on their antipsychotic prescribing. We compared the characteristics of physicians who did and did not engage with the intervention, and assessed early changes in prescribing.Entities:
Keywords: Antipsychotic prescribing; Audit and feedback; Interrupted time series; Nursing homes
Year: 2020 PMID: 32885189 PMCID: PMC7427908 DOI: 10.1186/s43058-020-00013-9
Source DB: PubMed Journal: Implement Sci Commun ISSN: 2662-2211
Fig. 1Study timeline
Fig. 2Cohort creation flow diagram
Baseline characteristics of physicians, nursing homes, and residents in Ontario, by patterns of signing up for a provincial audit and feedback initiative
| Variable | Physicians who did not sign up, | Physicians who signed up, | Total, | |
|---|---|---|---|---|
| Physician characteristics | ||||
| Sex | ||||
| Female | 181 (25.6%) | 59 (24.9%) | 240 (25.4%) | 0.83 |
| Male | 526 (74.4%) | 178 (75.1%) | 704 (74.6%) | |
| Age (mean ± SD) | 57.60 ± 11.16 | 56.98 ± 10.66 | 57.45 ± 11.03 | 0.45 |
| Years practicing (mean ± SD) | 30.93 ± 12.06 | 30.40 ± 11.37 | 30.80 ± 11.89 | 0.546 |
| Medical graduate location | ||||
| Foreign graduate | 149 (21.1%) | 34 (14.3%) | 183 (19.4%) | 0.02 |
| Canadian graduate | 558 (78.9%) | 203 (85.7%) | 761 (80.6%) | |
| Number of LTC residents per month (mean ± SD) | 49.63 ± 53.38 | 66.35 ± 57.77 | 53.83 ± 54.97 | |
| Number of LTC billings per month (mean ± SD) | 88.54 ± 114.37 | 127.72 ± 162.45 | 98.49 ± 129.33 | |
| Percent of total billings in month in LTC (mean ± SD) | 17.65 ± 24.22 | 26.87 ± 28.40 | 19.99 ± 25.65 | |
| Nursing home characteristics | ||||
| Number of beds in primary LTC home (mean ± SD) | 128 (88–179) | 150 (97–200) | 128 (90–189) | |
| Setting of primary LTC home | ||||
| Urban | 539 (76.2%) | 201 (84.8%) | 740 (78.4%) | |
| Rural | 168 (23.8%) | 36 (15.2%) | 204 (21.6%) | |
| Ownership status of primary LTC home | ||||
| Non-profit | 329 (46.5%) | 114 (48.1%) | 443 (46.9%) | 0.346 |
| Profit | 372 (52.6%) | 123 (51.9%) | 495 (52.4%) | |
| Unknown | 6 (0.8%) | 0 (0.0%) | 6 (0.6%) | |
| Resident characteristics | ||||
| Sex | ||||
| Female | 25,335 (72.2%) | 11,308 (71.9%) | 36,643 (72.1%) | 0.498 |
| Male | 9756 (27.8%) | 4418 (28.1%) | 14,174 (27.9%) | |
| Age (mean ± SD) | 86.4 ± 7.5 | 86.4 ± 7.5 | 86.4 ± 7.5 | 0.731 |
| Time in LTC (cat.) | ||||
| < 1 year | 7223 (20.6%) | 3370 (21.4%) | 10,593 (20.8%) | 0.03 |
| 1–4 years | 18,746 (53.4%) | 8387 (53.3%) | 27,133 (53.4%) | |
| 5–9 years | 7386 (21.0%) | 3167 (20.1%) | 10,553 (20.8%) | |
| 10+ years | 1736 (4.9%) | 802 (5.1%) | 2538 (5.0%) | |
| Charlson comorbidity score (mean ± SD) | 0.9 ± 1.5 | 0.9 ± 1.4 | 0.9 ± 1.5 | 0.233 |
| Diabetes* | 9413 (26.8%) | 4060 (25.8%) | 13,473 (26.5%) | 0.017 |
| Hypertension* | 23,137 (65.9%) | 10,320 (65.6%) | 33,457 (65.8%) | 0.495 |
| Arteriosclerotic heart disease* | 5501 (15.7%) | 2294 (14.6%) | 7795 (15.3%) | |
| Congestive heart failure* | 3886 (11.1%) | 1648 (10.5%) | 5534 (10.9%) | 0.047 |
| Peripheral vascular disease* | 1935 (5.5%) | 892 (5.7%) | 2827 (5.6%) | 0.473 |
| Deep vein thrombosis* | 447 (1.3%) | 196 (1.2%) | 643 (1.3%) | 0.798 |
| Cardiac dysrhythmia* | 2449 (7.0%) | 1148 (7.3%) | 3597 (7.1%) | 0.192 |
| Alzheimer’s or dementia* | 24,057 (68.6%) | 11,018 (70.1%) | 35,075 (69.0%) | |
| Cancer* | 2950 (8.4%) | 1306 (8.3%) | 4256 (8.4%) | 0.701 |
| Obstructive airway disease* | 6073 (17.3%) | 2674 (17.0%) | 8747 (17.2%) | 0.403 |
| Depression* | 11,793 (33.6%) | 5168 (32.9%) | 16,961 (33.4%) | 0.1 |
| Psychosis* | 1603 (4.6%) | 725 (4.6%) | 2328 (4.6%) | 0.834 |
| Arthritis* | 480 (1.4%) | 238 (1.5%) | 718 (1.4%) | 0.199 |
| Parkinson’s disease* | 2533 (7.2%) | 1156 (7.4%) | 3689 (7.3%) | 0.595 |
| Level of function (activities of daily living)* (mean ± SD) | 16.9 ± 7.2 | 16.9 ± 7.4 | 16.9 ± 7.3 | 0.603 |
| Pain score* (mean ± SD) | 0.4 ± 0.7 | 0.4 ± 0.7 | 0.4 ± 0.7 | 0.901 |
| Depression rating score* (mean ± SD) | 2.0 ± 2.4 | 2.1 ± 2.4 | 2.0 ± 2.4 | |
| Likelihood of falls scale* | ||||
| Low risk of falls | 29,535 (84.2%) | 13,116 (83.4%) | 42,651 (83.9%) | |
| Medium/high risk of falls | 5556 (15.8%) | 2610 (16.6%) | 8166 (16.1%) | |
| Aggressive behavior scale* (mean ± SD) | 1.4 ± 2.1 | 1.5 ± 2.3 | 1.4 ± 2.2 | |
| Frailty index* | ||||
| Robust (score < 0.2) | 5319 (15.2%) | 2385 (15.2%) | 7704 (15.2%) | 0.307 |
| Pre-frail (score = 0.2 to 0.3) | 10,773 (30.7%) | 4725 (30.0%) | 15,498 (30.5%) | |
| Frail (score > 0.3) | 18,999 (54.1%) | 8616 (54.8%) | 27,615 (54.3%) | |
| ED visits in past year | 12,862 (36.7%) | 5570 (35.4%) | 18,432 (36.3%) | 0.007 |
| Mean ± SD | 0.7 ± 1.4 | 0.7 ± 1.4 | 0.7 ± 1.4 | 0.127 |
| Any inpatient hospitalizations in past year | 6520 (18.6%) | 2861 (18.2%) | 9381 (18.5%) | 0.298 |
| Any psychiatric consult in past year | 4498 (12.8%) | 2029 (12.9%) | 6527 (12.8%) | 0.793 |
| Any geriatric consult in past year | 2031 (5.8%) | 922 (5.9%) | 2953 (5.8%) | 0.738 |
| Any antipsychotic use | 9596 (27.3%) | 4178 (26.6%) | 13,774 (27.1%) | 0.068 |
| Any statin use | 6209 (17.7%) | 2551 (16.2%) | 8760 (17.2%) | |
| Any benzodiazepine use | 4359 (12.4%) | 1809 (11.5%) | 6168 (12.1%) | |
IQR interquartile range, LTC long-term care
*Captured from the most recent Resident Assessment Instrument data
Baseline physician and resident characteristics by report view
| Variable | Physicians with no report views, | Physicians with at least one report view, | Total, | |
|---|---|---|---|---|
| Physician characteristics | ||||
| Sex | ||||
| Female | 18 (23.1%) | 36 (27.3%) | 54 (25.7%) | 0.501 |
| Male | 60 (76.9%) | 96 (72.3%) | 156 (74.3%) | |
| Age (mean ± SD) | 55.7 ± 10.1 | 53.7 ± 11.1 | 54.4 ± 10.8 | 0.204 |
| Years practicing (mean ± SD) | 28.9 ± 10.9 | 27.1 ± 11.9 | 28 (20–36) | 0.284 |
| Medical graduate location | ||||
| Foreign graduate | 16 (20.5%) | 11 (8.3%) | 27 (12.9%) | |
| Canadian graduate | 62 (79.5%) | 121 (91.7%) | 183 (87.1%) | |
| Number of LTC residents per month (mean ± SD) | 59.7 ± 55.4 | 63.8 ± 54.1 | 62.3 ± 54.5 | 0.602 |
| Number of LTC billings per month (mean ± SD) | 138.8 ± 195.7 | 109.8 ± 114.6 | 120.6 ± 150.1 | 0.176 |
| Percent of total billings in month in LTC (mean ± SD) | 20.2 ± 23.6 | 25.4 ± 29.8 | 23.4 ± 27.7 | 0.191 |
| Nursing home characteristics | ||||
| Number of beds in primary LTC home (mean ± SD) | 169.2 ± 102.1 | 160.9 ± 77.6 | 164.0 ± 87.4 | 0.503 |
| Setting of primary LTC home | ||||
| Urban | 69 (88.5%) | 108 (81.8%) | 177 (84.3%) | 0.201 |
| Rural | 9 (11.5%) | 24 (18.2%) | 33 (15.7%) | |
| Ownership status of primary LTC home | ||||
| Non-profit | 38 (48.7%) | 67 (50.8%) | 105 (50.0%) | 0.775 |
| Profit | 40 (51.3%) | 65 (49.2%) | 105 (50.0%) | |
| Resident characteristics | ||||
| Sex | ||||
| Female | 6144 (70.2%) | 10,632 (68.9%) | 16,776 (69.4%) | 0.045 |
| Male | 2614 (29.8%) | 4795 (31.1%) | 7409 (30.6%) | |
| Age (mean ± SD) | 85.8 ± 7.5 | 85.3 ± 7.5 | 85.5 ± 7.5 | |
| Time in LTC (cat.) | ||||
| < 1 year | 4502 (51.4%) | 7721 (50.0%) | 12,223 (50.5%) | 0.082 |
| 1–4 years | 3070 (35.1%) | 5455 (35.4%) | 8525 (35.2%) | |
| 5–9 years | 1001 (11.4%) | 1887 (12.2%) | 2888 (11.9%) | |
| 10+ years | 185 (2.1%) | 364 (2.4%) | 549 (2.3%) | |
| Charlson comorbidity score (mean ± SD) | 1.2 ± 1.7 | 1.2 ± 1.6 | 1.2 ± 1.7 | 0.041 |
| Diabetes* | 2280 (26.0%) | 3964 (25.7%) | 6244 (25.8%) | 0.564 |
| Hypertension* | 5775 (65.9%) | 9917 (64.3%) | 15,692 (64.9%) | |
| Arteriosclerotic heart disease* | 1238 (14.1%) | 2197 (14.2%) | 3435 (14.2%) | 0.821 |
| Congestive heart failure* | 1132 (12.9%) | 1776 (11.5%) | 2908 (12.0%) | |
| Peripheral vascular disease* | 526 (6.0%) | 893 (5.8%) | 1419 (5.9%) | 0.489 |
| Deep vein thrombosis* | 113 (1.3%) | 171 (1.1%) | 284 (1.2%) | 0.207 |
| Cardiac dysrhythmia* | 692 (7.9%) | 1091 (7.1%) | 1783 (7.4%) | 0.018 |
| Alzheimer’s or dementia* | 15,965 (66.0%) | 5685 (64.9%) | 10,280 (66.6%) | |
| Cancer* | 822 (9.4%) | 1276 (8.3%) | 2098 (8.7%) | |
| Obstructive airway disease* | 1583 (18.1%) | 2651 (17.2%) | 4234 (17.5%) | 0.08 |
| Depression* | 2556 (29.2%) | 4231 (27.4%) | 6787 (28.1%) | |
| Psychosis* | 431 (4.9%) | 795 (5.2%) | 1226 (5.1%) | 0.429 |
| Arthritis* | 139 (1.6%) | 204 (1.3%) | 343 (1.4%) | 0.094 |
| Parkinson’s disease* | 665 (7.6%) | 1065 (6.9%) | 1730 (7.2%) | 0.046 |
| Level of function* (activities of daily living) (mean ± SD) | 15.8 ± 7.3 | 15.6 ± 7.5 | 15.7 ± 7.4 | 0.039 |
| Pain score* (mean ± SD) | 0.5 ± 0.8 | 0.5 ± 0.7 | 0.5 ± 0.8 | |
| Depression rating score* (mean ± SD) | 1.9 ± 2.3 | 1.9 ± 2.2 | 1.9 ± 2.3 | 0.143 |
| Likelihood of falls scale* | ||||
| Low risk of falls | 7137 (81.5%) | 12,618 (81.8%) | 19,755 (81.7%) | 0.562 |
| Medium/high risk of falls | 1621 (18.5%) | 2809 (18.2%) | 4430 (18.3%) | |
| Aggressive behavior scale* (mean ± SD) | 1.4 ± 2.2 | 1.4 ± 2.2 | 1.4 ± 2.2 | 0.18 |
| Frailty index* | ||||
| Robust (score ≤ 0.2) | 1550 (17.7%) | 2894 (18.8%) | 4444 (18.4%) | 0.112 |
| Pre-Frail (score = 0.2 to 0.3) | 2964 (33.8%) | 5192 (33.7%) | 8156 (33.7%) | |
| Frail (score ≥ 0.3) | 4244 (48.5%) | 7341 (47.6%) | 11,585 (47.9%) | |
| ER visits in past year | 4945 (56.5%) | 8475 (54.9%) | 13,420 (55.5%) | 0.022 |
| Any inpatient hospitalization | 3403 (38.9%) | 5749 (37.3%) | 9152 (37.8%) | 0.014 |
| Any psychiatric consult in past year | 1435 (16.4%) | 2241 (14.5%) | 3676 (15.2%) | |
| Any geriatric consult in past year | 1218 (13.9%) | 2060 (13.4%) | 3278 (13.6%) | 0.226 |
| Any antipsychotic use | 2663 (30.4%) | 4792 (31.1%) | 7455 (30.8%) | 0.288 |
| Any statin use | 1796 (20.5%) | 3154 (20.4%) | 4950 (20.5%) | 0.908 |
| Any benzodiazepine use | 1077 (12.3%) | 1936 (12.5%) | 3013 (12.5%) | 0.568 |
IQR interquartile range, LTC long-term care
*Captured from the most recent Resident Assessment Instrument data
Fig. 3Adjusted antipsychotic prescribing at each time period, by exposure group. Adjusted for nursing home variables (number of beds, urban vs. rural location, private vs. public institution), physician variables (sex, age, years practicing, Canadian vs. foreign graduate, number of nursing home residents, number of nursing home institutions practicing, percent of billings in nursing homes), and resident characteristics (sex, age, time in nursing home, Charlson comorbidity scale, diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral vascular disease, deep vein thrombosis, cardiac dysrhythmia, Alzheimer’s, dementia, cancer, obstructive airway disease, depression, arthritis, Parkinson’s disease, activities of daily living scale, pain score, depression rating scale, likelihood of falls scale, aggressive behavior scale, frailty index, emergency department visits in past year, inpatient hospitalizations in past year, any phychiatric consult in past year, any geriatric consult in past year, any benzodiazepine use)
Fig. 4Adjusted difference in percentage of days patient is on antipsychotic, relative to baseline-quarter. Adjusted for nursing home variables (number of beds, urban vs. rural location, private vs. public institution), physician variables (sex, age, years practicing, Canadian vs. foreign graduate, number of nursing home residents, number of nursing home institutions practicing, percent of billings in nursing homes), and resident characteristics (sex, age, time in nursing home, Charlson comorbidity scale, diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral vascular disease, deep vein thrombosis, cardiac dysrhythmia, Alzheimer’s, dementia, cancer, obstructive airway disease, depression, arthritis, Parkinson’s disease, activities of daily living scale, pain score, depression rating scale, likelihood of falls scale, aggressive behavior scale, frailty index, emergency department visits in past year, inpatient hospitalizations in past year, any psychiatric consult in past year, any geriatric consult in past year, any benzodiazepine use)
Prescription rates: within-group changes over time
| Time | Did not sign up, | Signed up but did not view, | Signed up and viewed report, |
|---|---|---|---|
| Mean percentage of nursing home days on antipsychotics | |||
| Baseline | 25.8 | 26.3 | 25.0 |
| 3 months | 25.4 | 25.6 | 24.1 |
| 6 months | 24.9 | 24.9 | 23.2 |
| Within-group changes over time ( | < 0.0001 | < 0.0001 | < 0.0001 |
| Change from baseline to 3 months: adjusted least square mean (95% CI) | − 0.41 (− 0.61, − 0.22) | − 0.72 (− 1.14, − 0.30) | − 0.89 (− 1.29, − 0.48) |
| Change from baseline to 6 months: adjusted least square mean (95% CI) | − 0.88 (− 1.14, − 0.62) | − 1.35 (− 1.93, − 0.77) | − 1.82 (− 2.37, − 1.27) |
| Mean percentage of nursing home days on benzodiazepines^ | |||
| Baseline | 10.5 | 9.8 | 10.2 |
| 3 months | 10.4 | 9.6 | 10.0 |
| 6 months | 10.3 | 9.7 | 9.7 |
| Within-group changes over time ( | 0.001 | 0.387 | 0.001 |
| Change from baseline to 3 months: adjusted least square mean (95% CI) | − 0.10 (− 0.21, 0.02) | − 0.18 (− 0.45, 0.08) | − 0.16 (− 0.41, 0.09) |
| Change from baseline to 3 months: adjusted least square mean (95% CI) | − 0.25 (− 0.38, − 0.12) | − 0.12 (− 0.41, 0.17) | − 0.52 (− 0.80, − 0.25) |
| Mean percentage of nursing home days on statins | |||
| Baseline | 17.5 | 16.4 | 16.5 |
| 3 months | 16.9 | 15.8 | 15.8 |
| 6 months | 16.2 | 15.2 | 15.0 |
| Within-group changes over time ( | < 0.0001 | < 0.0001 | < 0.0001 |
| Change from baseline to 3 months: adjusted least square mean (95% CI) | − 0.54 (− 0.64, − 0.44) | − 0.54 (− 0.76, − 0.32) | − 0.61 (− 0.82, − 0.40) |
| Change from baseline to 3 months: adjusted least square mean (95% CI) | − 1.20 (− 1.35, − 1.05) | − 1.17 (− 1.51, − 0.84) | − 1.44 (− 1.76, − 1.12) |
Multivariable linear mixed effects regression adjusted for the following: nursing home variables (number of beds, urban vs. rural location, private vs. public institution), physician variables (sex, age [cont.], years practicing [cont.], Canadian vs. foreign graduate, number of nursing home residents [cont.], number of nursing home institutions practicing in [cont.], percent of billings in nursing homes), and resident characteristics (sex, age [cont.] time in nursing home [cont.], Charlson comorbidity scale [cont.], diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral vascular disease, deep vein thrombosis, cardiac dysrhythmia, Alzheimer’s, dementia, cancer, obstructive airway disease, depression, arthritis, Parkinson’s disease, activities of daily living scale, pain score, depression rating scale, likelihood of falls scale, aggressive behavior scale, frailty index, emergency room visits in past year [cont.], inpatient hospitalizations in past year [cont.], any psychiatric consult in past year, any geriatric consult in past year, any benzodiazepine use). Analyses restricted to physicians who signed up in time for the initial release of the intervention
^Any benzodiazepine use dropped from adjustment in this model
Prescription rates: pairwise comparisons for changes over 6 months from baseline
| Change | Adjusted least square mean difference (% scale) | 95% confidence interval | |
|---|---|---|---|
| Mean percentage of nursing home days on antipsychotics | |||
| Report view vs. no sign up | − 0.94 | − 1.54, − 0.35 | |
| No report view vs. no sign up | − 0.47 | − 1.09, 0.15 | 0.137 |
| Report view vs. no report view | − 0.47 | − 1.26, 0.31 | 0.239 |
| Mean percentage of nursing home days on benzodiazepines* | |||
| Report view vs. no sign up | − 0.27 | − 0.57, 0.02 | 0.071 |
| No report view vs. no sign up | 0.12 | − 0.19, 0.44 | 0.433 |
| Report view vs. no report view | − 0.40 | − 0.79, 0.00 | 0.048 |
| Mean percentage of nursing home days on statins | |||
| Report view vs. no sign up | − 0.24 | − 0.58, 0.10 | 0.171 |
| No report view vs. no sign up | 0.02 | − 0.33, 0.38 | 0.893 |
| Report view vs. no report view | − 0.26 | − 0.72, 0.19 | 0.254 |
Multivariable linear mixed effects regression adjusted for the following: nursing home variables (number of beds, urban vs. rural location, private vs. public institution), physician variables (sex, age [cont.], years practicing [cont.], Canadian vs. foreign graduate, number of nursing home residents [cont.], number of nursing home institutions practicing in [cont.], percent of billings in nursing homes), and resident characteristics (sex, age [cont.] time in nursing home [cont.], Charlson comorbidity scale [cont.], diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral vascular disease, deep vein thrombosis, cardiac dysrhythmia, Alzheimer’s, dementia, cancer, obstructive airway disease, depression, arthritis, Parkinson’s disease, activities of daily living scale, pain score, depression rating scale, likelihood of falls scale, aggressive behavior scale, frailty index, emergency room visits in past year [cont.], inpatient hospitalizations in past year [cont.], any psychiatric consult in past year, any geriatric consult in past year, any benzodiazepine use). Analyses restricted to physicians who signed up in time for the initial release of the intervention
*Any benzodiazepine use dropped from adjustment in this model